Abstract
Background Local antibiotic applications have been used in osteomyelitis as an adjunctive treatment method. Biodegradable materials are also used for the same purpose by adding antibiotics. The fact that it does not require additional surgery to be removed is an important advantage. The current study is therefore intended to develop a biodegradable drug-loaded polymeric scaffold with a good antibiotic release that can be an alternative to antibiotic-impregnated bone cement.
Methods A tissue scaffold containing poly (2-hydroxyethyl methacrylate) (PHEMA) was prepared in our laboratory and loaded with Ertapenem and Daptomycin(E&D) antibiotics.
To evaluate drug release kinetics, the absorbance values of the scaffold loaded with E&D were measured with the spectrometer.
For microbiological tests, (E&D) impregnated cement and scaffold, as well as the control scaffold and cement samples were investigated for their antibacterial activities on Staphylococcus aureus and Klebsiella pneumoniae strains using the disc diffusion method.
Results The Daptomycin zone diameter in S. aureus ATCC strain was 17 mm, 24 mm for scaffold, and 22 mm for cement. Scaffold was found to be more effective than cement against S. aureus strain. On K. pneumoniae ATCC strain, it was found that this strain was resistant to Ertapenem, but the zone diameter was 21 mm for scaffold and 20 mm for cement. Ertapenem-loaded scaffold was found to be more effective than cement.
When we evaluated the release profiles, for the Daptomycin-loaded cement group, 98%of Daptomycin was cumulatively released within 30 min, and for the Daptomycin-loaded scaffold group, 100%of Daptomycin was cumulatively released in 6 days. To compare Ertapenem- loaded cement and scaffold, 98% of Ertapenem was cumulatively released within 10 min in the cement group. For the scaffold group, 100% of Ertapenem was cumulatively released in 17 days. It was found that e scaffold released the antibiotic more slowly and for a longer duration.
Competing Interest Statement
The authors have declared no competing interest.
Funding Statement
Petek Konya Afyonkarahisar Health Science University, Scientific Research Project Coordination Unit, Project Number 22.GENEL.016.
Author Declarations
I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.
Yes
The details of the IRB/oversight body that provided approval or exemption for the research described are given below:
.
I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines, such as any relevant EQUATOR Network research reporting checklist(s) and other pertinent material, if applicable.
Yes
Footnotes
e-mail. nurikonya{at}hotmail.com, E-mail: yilmazbk{at}gmail.com, e-mail. elif.kaga{at}afsu.edu.tr, E-mail: skaga{at}aku.edu.tr, e-mail:dryelizcetinkol{at}gmail.com
Data Availability
Data cannot be shared publicly because of [Afyonkarahisar Health Science University.
